Mirtazapine Ab (Mirtazapine)

Mirtazapine works by blocking presynaptic α2‑adrenergic receptors, which increases norepinephrine release, and by antagonizing 5‑HT2 and 5‑HT3 serotonin receptors. Its strong H1‑histamine antagonism also contributes to sedation and appetite stimulation, together producing an antidepressant effect.

The appropriate dose of Mirtazapine Ab is determined by the prescribing clinician based on the individual’s medical condition, response to therapy, and tolerability. Dosage adjustments are made according to clinical judgment and patient needs.

Safety data for mirtazapine in pregnancy and lactation are limited. The prescriber should evaluate the potential benefits against possible risks to the fetus or infant before initiating therapy in pregnant or nursing women.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Compared with selective serotonin reuptake inhibitors (SSRIs), mirtazapine has a distinct mechanism that often results in greater sedation and appetite stimulation, making it useful for patients with insomnia or weight loss. It may be chosen when SSRIs are ineffective or poorly tolerated.

Mirtazapine Ab tablets should be stored at room temperature, below 25 °C, in the original packaging to protect from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged.

Mirtazapine Ab is taken orally, usually once daily in the evening due to its sedative effect. The tablet should be swallowed whole with water and not chewed or crushed unless otherwise directed by a healthcare professional.

Serious risks include agranulocytosis, severe hypersensitivity reactions, seizures, hepatotoxicity, and the emergence or worsening of suicidal thoughts, particularly during the initial weeks of treatment. Patients should be monitored closely for these events.

Mirtazapine is contraindicated in patients who have taken monoamine oxidase inhibitors within the past 14 days, those with known hypersensitivity to the drug, and individuals with severe hepatic impairment without appropriate dose adjustment.